A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Lenalidomide (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 14 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2017 Planned End Date changed from 1 Feb 2019 to 30 Nov 2019.